MRUS MERUS B V

Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

UTRECHT, Netherlands, May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., President, Chief Executive Officer and Principal Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2019 Healthcare Conference on Wednesday, May 22, 2019, at 8:30 a.m. ET.

A live webcast of the event will be available on the Investors and Media page of the Company's website, . A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information on the company and programs, please visit Merus’ website, .

Investor and Media Inquiries:

Jillian Connell

Merus N.V.

Investor Relations and Corporate Communications

617-955-4716

 

EN
20/05/2019

Underlying

MRUSMERUS B V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MERUS B V

Jacob Mekhael
  • Jacob Mekhael
MRUS MERUS B V

Merus Petosemtamab phase 2 mCRC results show high response rates

Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...

10/27/25 October 27, 2025 1 EN
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thomas Couvreur
BFIT BASIC-FIT NV
EXM EXMAR N.V.
UCB UCB S.A.
MRUS MERUS B V
JDEP JDE PEET'S NV
BAR BARCO NV
HYL HYLORIS PHARMACEUTICALS
10/27/25 October 27, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer De...

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ...

October 24, 2025 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Hoste
HEIA HEINEKEN NV
PROX Proximus SA de ... ... (+9)

Morning Notes : ABI BB, ASML NA, BAR BB, OPTI BB, HEIA NA, IVA FP, PRO...

: ABI BB, ASML NA, BAR BB, OPTI BB, HEIA NA, IVA FP, PROX BB, SEQUA BB, MRUS US

HEIA HEINEKEN NV
PROX PROXIMUS SA DE DROIT PUBLIC
OPTI CRESCENT
ABI ANHEUSER-BUSCH INBEV SA/NV
MRUS MERUS B V
IVA INVENTIVA SA
ASML ASML HOLDING NV
SEQUA SEQUANA MEDICAL
BAR BARCO NV
10/15/25 October 15, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus Announces Publication of an Abstract on Petosemtamab in Metastat...

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Bicloni...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch